BioMarin to Participate in the BofA Securities 2022 Healthcare Conference, Thursday, May 12 at 8:40amPT/11:40amET
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced that CEO Jean-Jacques Bienaimé will present at the BofA Securities Healthcare Conference on May 12, 2022, at 8:40 am PT/11:40 am ET in Las Vegas.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced that CEO Jean-Jacques Bienaimé will present at the BofA Securities Healthcare Conference on May 12, 2022, at 8:40 am PT/11:40 am ET in Las Vegas. Interested individuals can access the live webcast on the BioMarin website. A replay will be available for 90 days post-event. BioMarin specializes in developing therapies for serious rare diseases, with a portfolio of seven commercial products and various clinical candidates.
Details
News Market Reaction – BMRN
The recorded move for BMRN in the trading session of this news was +1.35%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN RAFAEL, Calif., May 4, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at the BofA Securities Healthcare Conference on May 12 at 8:40am PT/11:40am ET in Las Vegas. To access the live webcast, please visit the BioMarin website, https://investors.biomarin.com/.
A replay of the webcast will be available for 90 days.
About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases.
For additional information, please visit www.biomarin.com.
Contacts: | |
Investors | Media |
Traci McCarty | Debra Charlesworth |
BioMarin Pharmaceutical Inc. | BioMarin Pharmaceutical Inc. |
(415) 455-7558 | (415) 455-7451 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-participate-in-the-bofa-securities-2022-healthcare-conference-thursday-may-12-at-840ampt1140amet-301539505.html
SOURCE BioMarin Pharmaceutical Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.